KNTPF News and Press, Kintor Pharmaceutical Ltd.

2023-12-07 20:28:00 ET Summary Kintor’s drug has failed to show a significant hair-boosting effect in Phase III trials, dashing investors’ hopes for a ground-breaking treatment for baldness. The disappointing test results triggered a 46% share plunge over five tradin...

2023-10-15 07:15:00 ET Summary Suzhou MediLink Therapeutics out-licenses global rights for its HER3 antibody-drug conjugate candidate to BioNTech in a $1.1 billion deal. Beijing AI drug discovery company BioMap forms a strategic collaboration with Sanofi to co-develop new protein ...

Summary Beijing CANbridge Pharma exercised an option for global rights to a novel second-gen gene therapy aimed at spinal muscular atrophy from UMass Chan medical school. Shanghai Zhimeng Biopharma signed an agreement to out-license global rights for its TLR8 agonist to GSK plc as an HB...

Summary Kintor Pharmaceutical Ltd. announced on Sunday that it will place 42 million shares, representing approximately 10.3% of its enlarged capital after the issue. Pursuant to the placement agreement, the company’s co-founder, Chairman and CEO Tong Youzhi first sold 42 million...

OrbiMed Asia V plans to raise $1.1 billion, OrbiMed Flagship IX seeks $1.9 billion and OrbiMed Royalty & Credit Opportunities $1.75 billion. Shanghai Jemincare Pharmaceuticals out-licensed global rights (ex-China) for a novel pain medication to Orion Corporation, a Finnish pharmac...

Shanghai's HanBio Therapeutics raised $40 million in a Series A financing to advance its innovative biologic products. HanBio’s pipeline includes three bispecific antibodies in the IND and pre-IND stages, and a variety of early-stage antibodies and other biologics products. Swe...

LianBio raised $325 million in its NASDAQ IPO at a market capitalization of $1.9 billion to support its drug in-licensings for China. Beijing Clover Biopharma completed a $260 million IPO in Hong Kong and will use the proceeds to continue development of Trimer-Tag vaccines, Trimer-Tag...

Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. The $1.4 billion landmark deal between Beijing's BeiGene and Celgene (now Bristol-Myers) is falling apart. The companies are arguing over BeiGene's C...

LianBio, a Princeton, NJ-Shanghai biopharma, has filed for a $100 million IPO on the NASDAQ exchange. According to a Bloomberg article, I-Mab is in wide-ranging discussions with US and EU biopharmas for a deal that could out-license an I-Mab asset or involve a direct investment in the...

Beijing InnoCare out-licensed ex-China rights for its BTK inhibitor to Biogen in a $937.5 million deal. Suzhou's Kintor Pharma will start a US Phase II trial of its treatment for male pattern baldness. Ascletis Pharma of Hangzhou started a China bridging trial of its FXR agonist f...